Quantcast

Industry news that matters to you.  Learn more

World Fusion and Lumenogix Announce Global Strategic Partnership

World Fusion Co., LTD and Lumenogix Inc. recently announced a strategic partnership to provide a complete solution for the pharmaceutical industry that integrates the World Fusion Life Sciences Knowledge Bank (LSKB) for accelerating drug discovery with the Lumenogix Bioinformatics-in-a-Box™ for analyzing Next Generation Sequencing (NGS) data.

Transcriptome Profiling Grants Launched to Support New Biomarker Discovery

Thermo Fisher Scientific will fast-track 12 translational research teams’ gene-expression profiling through an innovative grant program launched today. Selected applicants will receive free next-generation RNA sequencing services to further their research in the field of cancer genomics.

Kalorama Report: Next Gen Sequencing Will Determine Growth in IVD Testing Market

Not since the commercialization of polymerase chain reaction tests has molecular diagnostics been presented with such a promising technology as next-generation sequencing (NGS), according to healthcare market research firm Kalorama Information.  NGS’s blue-chip status was discussed in the recently published The Worldwide Market for In Vitro Diagnostics, 9th Edition.

MolecularHealth Collaborates with SAP to Offer Innovative Employer Oncology Program

MolecularHealth recently announced the official launch of MolecularHealth™ COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP™. COPE enables self-funded employers to offer access to TreatmentMAP to their employees via a pre-packaged offering, which includes materials for employees, as well as working closely with patients’ physicians through the process of testing, analyzing and receiving results. SAP is working with MolecularHealth to become one of the first organizations to provide its employees with access to COPE and plans to offer it in the third quarter of 2014.

MolecularHealth Collaborates with SAP to Offer Innovative Employer Oncology Program

MolecularHealth recently announced the official launch of MolecularHealth™ COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP™. COPE enables self-funded employers to offer access to TreatmentMAP to their employees via a pre-packaged offering, which includes materials for employees, as well as working closely with patients’ physicians through the process of testing, analyzing and receiving results. SAP is working with MolecularHealth to become one of the first organizations to provide its employees with access to COPE and plans to offer it in the third quarter of 2014.